Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 22, 2018 19:30 ET | Source: Crown Bioscience

CBT製藥與中美冠科簽訂Ctla-4抗體許可證協議增加免疫腫瘤業務管線

美國加州普萊森頓訊, March 23, 2018 (GLOBE NEWSWIRE) -- 位于美國的CBT制藥公司（CBT Pharmaceuticals）同中美冠科簽訂了一項戰略性許可協議並發表聯合聲明承諾將一起為腫瘤聯合療法的發展共同努力。此協議將授權CBT制藥擁有中美冠科新型重組的靶向CTLA-4的人源單克隆抗體的全球獨家開發許可權：...
March 22, 2018 09:34 ET | Source: Crown Bioscience

CBT Pharmaceuticals to Grow Immuno-Oncology Pipeline by License Agreement of CrownBio CTLA-4 Antibody

SAN DIEGO, March 22, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
March 13, 2018 08:00 ET | Source: Crown Bioscience

CrownBio Enters Strategic Partnership with Phanes Therapeutics to Accelerate Discovery and Development of Phanes’ Novel Oncology Agents

SAN DIEGO, March 13, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
March 09, 2018 08:00 ET | Source: Crown Bioscience

Crown Bioscience to Showcase Scientific Expertise at Cambridge UK Symposium: Preclinical Evaluation of Novel Immunotherapies

SAN DIEGO, March 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
February 27, 2018 08:00 ET | Source: Crown Bioscience

Webinar to Reveal Data Supporting the Use of MuScreen™ for Preclinical Immunotherapeutic Development

SAN DIEGO, Feb. 27, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
February 20, 2018 08:00 ET | Source: Crown Bioscience

CAR T-Cell Therapy Platform

SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
February 09, 2018 08:00 ET | Source: Crown Bioscience

Enhanced MuScreen™ Platform Revolutionizes Preclinical Development of Immunotherapeutics

SAN DIEGO, Feb. 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
January 23, 2018 08:40 ET | Source: Crown Bioscience

Data on Novel Humanized Models for Targeted Immunotherapy Development, a CrownBio Conference Talk on January 24th, 2018

SAN DIEGO, Jan. 23, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
January 17, 2018 08:01 ET | Source: Crown Bioscience

Innovative Humanized Research Strategies for Immuno-Oncology Drug Development, Crown Bioscience Hosts a Live Webinar

SAN DIEGO, Jan. 17, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...
January 09, 2018 08:00 ET | Source: Crown Bioscience

Crown Bioscience Launches CrownSyn™, an Innovative Bioinformatics Solution that Simplifies the Characterization of Two-Drug Combination Studies

SAN DIEGO, Jan. 09, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company...